January 12-15, 2026 | San Francisco Marriott Marquis, CA
Clinical stage drug development company. Most advanced program is BTB-101 (a nonopioid analgesic in P2). Other portfolios include small molecule based RNA splicing modifiers for rare diseases and immuno-oncology indications.